Lexicon Pharmaceuticals Stock Forecast, Price & News

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Lexicon Pharmaceuticals in the last twelve months. There are currently 4 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" Lexicon Pharmaceuticals stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in LXRX, but not buy additional shares or sell existing shares.
View analyst ratings for Lexicon Pharmaceuticals or view top-rated stocks.

Wall Street analysts have given Lexicon Pharmaceuticals a "Hold" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Lexicon Pharmaceuticals wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Lexicon Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Thursday, November 4th 2021.
View our earnings forecast for Lexicon Pharmaceuticals.

Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) posted its earnings results on Friday, July, 30th. The biopharmaceutical company reported ($0.13) earnings per share (EPS) for the quarter, beating the Zacks' consensus estimate of ($0.16) by $0.03. The biopharmaceutical company earned $0.23 million during the quarter, compared to analyst estimates of $0.03 million. Lexicon Pharmaceuticals had a net margin of 536.83% and a trailing twelve-month return on equity of 27.59%.
View Lexicon Pharmaceuticals' earnings history.

Lexicon Pharmaceuticals' stock was trading at $2.27 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, LXRX shares have increased by 101.8% and is now trading at $4.58.
View which stocks have been most impacted by COVID-19.

6 Wall Street analysts have issued 1-year price objectives for Lexicon Pharmaceuticals' shares. Their forecasts range from $7.00 to $20.00. On average, they expect Lexicon Pharmaceuticals' share price to reach $12.00 in the next year. This suggests a possible upside of 162.0% from the stock's current price.
View analysts' price targets for Lexicon Pharmaceuticals or view top-rated stocks among Wall Street analysts.

9 employees have rated Lexicon Pharmaceuticals CEO Lonnel Coats on Glassdoor.com. Lonnel Coats has an approval rating of 100% among Lexicon Pharmaceuticals' employees. This puts Lonnel Coats in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

Some companies that are related to Lexicon Pharmaceuticals include Amgen (AMGN), Gilead Sciences (GILD), Regeneron Pharmaceuticals (REGN), Vertex Pharmaceuticals (VRTX), Biogen (BIIB), Seagen (SGEN), Alnylam Pharmaceuticals (ALNY), Exact Sciences (EXAS), Novavax (NVAX), Incyte (INCY), Repligen (RGEN), BioMarin Pharmaceutical (BMRN), United Therapeutics (UTHR), Neurocrine Biosciences (NBIX) and Exelixis (EXEL).
View all of LXRX's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Lexicon Pharmaceuticals investors own include Portola Pharmaceuticals (PTLA), Sarepta Therapeutics (SRPT), ACADIA Pharmaceuticals (ACAD), Dynavax Technologies (DVAX), MannKind (MNKD), ImmunoGen (IMGN), Geron (GERN), Micron Technology (MU), TherapeuticsMD (TXMD) and Gilead Sciences (GILD).

Lexicon Pharmaceuticals trades on the NASDAQ under the ticker symbol "LXRX."

Lexicon Pharmaceuticals' stock is owned by many different retail and institutional investors. Top institutional shareholders include FMR LLC (5.15%), BlackRock Inc. (3.22%), Vanguard Group Inc. (2.75%), Pinnacle Associates Ltd. (1.52%), Geode Capital Management LLC (0.89%) and State Street Corp (0.72%). Company insiders that own Lexicon Pharmaceuticals stock include Alexander A Santini, Christopher J Sobecki, James F Tessmer and Lonnel Coats.
View institutional ownership trends for Lexicon Pharmaceuticals.

LXRX stock was sold by a variety of institutional investors in the last quarter, including FMR LLC, Morgan Stanley, Morgan Stanley, Renaissance Technologies LLC, Bank of America Corp DE, AXA S.A., Squarepoint Ops LLC, and Bridgeway Capital Management LLC.
View insider buying and selling activity for Lexicon Pharmaceuticals or view top insider-selling stocks.

LXRX stock was bought by a variety of institutional investors in the last quarter, including BlackRock Inc., Dimensional Fund Advisors LP, State Street Corp, Wells Fargo & Company MN, Nuveen Asset Management LLC, Geode Capital Management LLC, Northern Trust Corp, and Swiss National Bank. Company insiders that have bought Lexicon Pharmaceuticals stock in the last two years include Alexander A Santini, Christopher J Sobecki, and Lonnel Coats.
View insider buying and selling activity for Lexicon Pharmaceuticals or or view top insider-buying stocks.

Shares of LXRX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of LXRX stock can currently be purchased for approximately $4.58.

Lexicon Pharmaceuticals has a market capitalization of $661.69 million and generates $24 million in revenue each year. The biopharmaceutical company earns $-58,570,000.00 in net income (profit) each year or ($0.52) on an earnings per share basis.

Lexicon Pharmaceuticals employs 78 workers across the globe.

Lexicon Pharmaceuticals was founded in 1995.

The official website for Lexicon Pharmaceuticals is www.lexpharma.com.

Lexicon Pharmaceuticals is headquartered at 8800 TECHNOLOGY FOREST PLACE, THE WOODLANDS TX, 77381.

Lexicon Pharmaceuticals' mailing address is 8800 TECHNOLOGY FOREST PLACE, THE WOODLANDS TX, 77381. The biopharmaceutical company can be reached via phone at (281) 863-3000 or via email at [email protected]